MONOCLONAL ANTI-CYBA ANTIBODY PRODUCED

Application

Monoclonal Anti-CYBA antibody produced in mouse has been used in: immunoblotting flow cytometry immunofluorescence

Biochem/physiol Actions

In prostate cancer cells downregulation of cytochrome b245, alpha polypeptide/light chain (CYBA) was reported to inhibited cell proliferation and colony formation, through AKT and ERK1/2 signaling pathways, indicating CYBA has a role in tumor angiogenesis and tumor growth. Mutations inthis genecauses an autosomal recessive forms of chronic granulomatous disease (AR220CGD).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-CYBA (mouse IgM isotype) is derived from the hybridoma CB-64 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to a sequence at the internal region of human CYBA, conjugated to keyhole limpet hemocyanin (KLH). The small subunit, p22phox subunit, also known as cytochrome b245, alpha polypeptide/light chain (CYBA) is membrane bound,which is expressed in phagocytic, endothelial and vascular smooth muscle cells. This gene is located on human chromosome16q24

Immunogen

Synthetic peptide corresponding to a sequence at the internal region of human CYBA .

Physical form

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative.